Related Experiment Video
Updated: Aug 23, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor?
Peter A McCullough1, Sandeep Soman
1Division of Cardiology, Department of Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA. pmc975@yahoo.com
Insights
Coronary artery calcification (CAC) in end-stage renal disease (ESRD) is linked to renal dysfunction and lipid profiles, not calcium-phosphorus balance. Statins may reduce CAC progression in ESRD patients.
Area of Science:
- Nephrology
- Cardiology
- Metabolic Disorders
Background:
- End-stage renal disease (ESRD) is associated with metabolic disorders, including soft tissue and coronary artery calcification (CAC).
- Key determinants of CAC in ESRD patients include the extent and duration of renal dysfunction and advanced age.
Purpose of the Study:
- To review the determinants of coronary artery calcification (CAC) in end-stage renal disease (ESRD) patients.
- To explore potential therapeutic strategies for managing CAC in this population.
Main Methods:
- Literature review of studies investigating CAC in ESRD.
- Analysis of factors influencing CAC progression, including lipid profiles and calcium-phosphorus balance.
Main Results:
- Lipid profiles, particularly low high-density lipoprotein cholesterol, elevated triglycerides, and elevated low-density lipoprotein cholesterol (LDL-C), are significant factors in CAC.
- Studies have not consistently found a causal link between calcium-phosphorus balance and CAC in ESRD.
- LDL-C reduction through statins or sevelamer may significantly decrease CAC progression from 25-30% to 0-6% annually.
Conclusions:
- CAC in ESRD is multifactorial, with renal dysfunction and lipid profiles playing key roles.
- The role of calcium-phosphorus balance in CAC progression remains uncertain.
- Further research is needed to elucidate CAC determinants and optimize treatments in ESRD patients.
Abstract:
End-stage renal disease (ESRD) is comprised of conditions associated with metabolic disorders associated with soft tissue and coronary artery calcification (CAC). The most consistent determinants of CAC in these patients are extent and duration of renal dysfunction and older age. The majority of published studies have not found a causal relationship between measures of calcium-phosphorus balance and CAC. When taken into consideration, the lipid profile [primarily low high-density lipoprotein cholesterol, elevated triglycerides, elevated low-density lipoprotein (LDL-C), and elevated total cholesterol] are important factors in the calcification process. Recent data seems to indicate that CAC is regulated both positively and negatively by a wide variety of mechanisms affecting patients with renal disease. The progression of CAC can be reduced from a 25% to 30% to 0% to 6% annual increase with LDL-C reduction caused by statins or possibly sevelamer. It is currently unclear whether the calcium-phosphorus balance and its related treatments are involved in CAC progression in ESRD patients. Further research into the determinants and potential treatments for CAC in association with ESRD is warranted.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Urinary Tract Calculi IV: Nutrition Therapy and Prevention

